Eikon Therapeutics/$EIKN
1D1W1MYTD1Y5YMAX
Capital at risk
About Eikon Therapeutics
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Ticker
- $EIKN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 384
- Headquarters
- Millbrae, United States
- Website
- eikontx.com
EIKN Metrics
BasicAdvanced
$428M
-
-$13.72
-
-
Price and volume
Market cap
$428M
52-week high
$17.40
52-week low
$7.55
Average daily volume
621K
Financial strength
Current ratio
9.892
Quick ratio
9.606
Long term debt to equity
0.52
Total debt to equity
0.541
Interest coverage (TTM)
-404.36%
Profitability
EBITDA (TTM)
-317.229
Management effectiveness
Valuation
Price to book
0.92
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-0.716
Free cash flow yield (TTM)
-139.57%
Free cash flow per share (TTM)
-11.04
Growth
What the Analysts think about EIKN
Analyst ratings (Buy, Hold, Sell) for Eikon Therapeutics stock.
Analyst projections of the future price of Eikon Therapeutics stock.
Bulls say / Bears say
EIK1001 produced encouraging Phase 2 NSCLC data, with a 63.1% objective response rate and 90.8% disease-control rate across 65 efficacy-evaluable participants. The programme has now moved into registrational Phase 2/3 testing in both NSCLC and melanoma. (StockTitan, Eikon Therapeutics)
An independent Data Monitoring Committee selected a single EIK1001 dose for the melanoma study and recommended that the Phase 2/3 trial continue as planned. That supports the programme’s safety and execution profile ahead of later efficacy readouts. (BioSpace)
Eikon ended the second quarter with $531.2 million in cash, cash equivalents and marketable securities, with management expecting funding into the second half of 2027. Seven ESMO abstracts spanning all four current clinical candidates also give investors several near-term data catalysts rather than reliance on one programme. (Eikon Therapeutics, Eikon Therapeutics)
The investment case still rests on early, non-randomised evidence: EIK1001’s NSCLC results came from a Phase 2 study, while pivotal data are years away. Promising response rates therefore have not yet proved a survival benefit. (Seeking Alpha)
EIK1003’s efficacy remains modest for a Phase 1/2 asset, with reported objective response rates of 14.3% as monotherapy and 24.5% with paclitaxel. The paclitaxel cohort also recorded Grade 3 or higher treatment-emergent adverse events in 75% of patients, which could limit its use. (StockTitan)
Eikon remains loss-making and says its $531.2 million cash position funds operations only into the second half of 2027. Continued expansion of global registrational trials could force another fundraising before approval, creating dilution risk. (Eikon Therapeutics, FinancialContent)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
EIKN Financial Performance
Revenues and expenses
EIKN Earnings Performance
Company profitability
Upcoming events
No upcoming events
EIKN News
AllArticlesVideos
Funds containing EIKN
AllEURGBP
Fund name | Fund size | $EIKN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.